Base de dados : MEDLINE
Pesquisa : D01.268.271.380 [Categoria DeCS]
Referências encontradas : 9 [refinar]
Mostrando: 1 .. 9   no formato [Detalhado]

página 1 de 1

  1 / 9 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26761207
[Au] Autor:Nafee SS; Shaheen SA; Al-Ramady AM
[Ad] Endereço:Physics Department, Faculty of Science, King Abdulaziz University, Jeddah, 20589, Saudi Arabia.
[Ti] Título:Nuclear Data Evaluation for Mass Chain A=217:Odd-Proton Nuclei.
[So] Source:PLoS One;11(1):e0146182, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Thallium (81(217)Tl, Bismuth (83(217)Bi), Astatine (85(217)At), Francium (87(217)Fr), Actinium (89(217)Ac) and Protactinium (91(217)Pa) are of odd-proton numbers among the mass chain A = 217. In the present work, the half-lives and gamma transitions for the six nuclei have been studied and adopted based on the recently published interactions or unevaluated nuclear data sets XUNDL. The Q (α) has been updated based on the recent published work of the Atomic Mass Evaluation AME2012 as well. Moreover, the total conversion electrons as well as the K-Shell to L-Shell, L-Shell to M-Shell and L-Shell to N-Shell Conversion Electron Ratios have been calculated using BrIcc code v2.3. An updated skeleton decay scheme for each of the above nuclei has been presented here. The decay hindrance factors (HF) calculated using the ALPHAD program, which is available from Brookhaven National Laboratory's website, have been calculated for the α- decay data sets for (221)Fr-, (221)Ac- and (221)Pa-α-decays.
[Mh] Termos MeSH primário: Partículas alfa
Prótons
[Mh] Termos MeSH secundário: Actínio/química
Astato/química
Bismuto/química
Elétrons
Frâncio/química
Raios gama
Meia-Vida
Probabilidade
Protoactínio/química
Radioisótopos
Síncrotrons
Tálio/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Protons); 0 (Radioisotopes); 0S6855V29M (Protactinium); 15TEQ7D2QF (Francium); AD84R52XLF (Thallium); NIK1K0956U (Actinium); U015TT5I8H (Bismuth); XI595HAL7H (Astatine)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160114
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0146182


  2 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24374072
[Au] Autor:Wang G; de Kruijff RM; Rol A; Thijssen L; Mendes E; Morgenstern A; Bruchertseifer F; Stuart MC; Wolterbeek HT; Denkova AG
[Ad] Endereço:Radiation Science and Technology, Delft University of Technology, Mekelweg 15, 2629 JB Delft, The Netherlands.
[Ti] Título:Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles.
[So] Source:Appl Radiat Isot;85:45-53, 2014 Feb.
[Is] ISSN:1872-9800
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Alpha radionuclide therapy is steadily gaining importance and a large number of pre-clinical and clinical studies have been carried out. However, due to the recoil effects the daughter recoil atoms, most of which are alpha emitters as well, receive energies that are much higher than the energies of chemical bonds resulting in decoupling of the radionuclide from common targeting agents. Here, we demonstrate that polymer vesicles (i.e. polymersomes) can retain recoiling daughter nuclei based on an experimental study examining the retention of (221)Fr and (213)Bi when encapsulating (225)Ac.
[Mh] Termos MeSH primário: Actínio/administração & dosagem
Actínio/química
[Mh] Termos MeSH secundário: Actínio/farmacocinética
Partículas alfa/uso terapêutico
Transporte Biológico Ativo
Bismuto/administração & dosagem
Bismuto/química
Bismuto/farmacocinética
Butadienos/química
Composição de Medicamentos
Frâncio/química
Células HeLa
Seres Humanos
Radioisótopos de Chumbo/química
Método de Monte Carlo
Tamanho da Partícula
Polietileno/química
Radioisótopos/química
Compostos Radiofarmacêuticos/administração & dosagem
Compostos Radiofarmacêuticos/química
Compostos Radiofarmacêuticos/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Butadienes); 0 (Lead Radioisotopes); 0 (Radioisotopes); 0 (Radiopharmaceuticals); 0 (poly(1,2-butadiene-b-ethylene oxide)); 15TEQ7D2QF (Francium); 9002-88-4 (Polyethylene); NIK1K0956U (Actinium); U015TT5I8H (Bismuth)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:140211
[Lr] Data última revisão:
140211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131231
[St] Status:MEDLINE


  3 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23556718
[Au] Autor:Borschevsky A; Pershina V; Eliav E; Kaldor U
[Ad] Endereço:Helmholtz Institute Mainz, Mainz D-55128, Germany.
[Ti] Título:Ab initio studies of atomic properties and experimental behavior of element 119 and its lighter homologs.
[So] Source:J Chem Phys;138(12):124302, 2013 Mar 28.
[Is] ISSN:1089-7690
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Static dipole polarizabilities of element 119 and its singly charged cation are calculated, along with those of its lighter homologs, Cs and Fr. Relativity is treated within the 4-component Dirac-Coulomb formalism and electron correlation is included by the single reference coupled cluster approach with single, double, and perturbative triple excitations (CCSD(T)). Very good agreement with available experimental values is obtained for Cs, lending credence to the predictions for Fr and element 119. The atomic properties in group-1 are largely determined by the valence ns orbital, which experiences relativistic stabilization and contraction in the heavier elements. As a result, element 119 is predicted to have a relatively low polarizability (169.7 a.u.), comparable to that of Na. The adsorption enthalpy of element 119 on Teflon, which is important for possible future experimental studies of this element, is estimated as 17.6 kJ/mol, the lowest among the atoms considered here.
[Mh] Termos MeSH primário: Césio/química
Frâncio/química
Teoria Quântica
[Mh] Termos MeSH secundário: Politetrafluoretileno/química
Termodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
15TEQ7D2QF (Francium); 1KSV9V4Y4I (Cesium); 9002-84-0 (Polytetrafluoroethylene)
[Em] Mês de entrada:1309
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130406
[St] Status:MEDLINE
[do] DOI:10.1063/1.4795433


  4 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16833657
[Au] Autor:Lee EP; Wright TG
[Ad] Endereço:School of Chemistry, University of Southampton, Highfield, Southampton, UK, SO17 1BJ. E.P.Lee@soton.ac.uk
[Ti] Título:Ground electronic states of RbO2+, CsO2+ and FrO2: the ionization energies of RbO2 and CsO2.
[So] Source:J Phys Chem A;109(14):3257-61, 2005 Apr 14.
[Is] ISSN:1089-5639
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Calculations are performed to establish the ground electronic states of RbO2+, CsO2+, and FrO2. In the case of the cations, both linear and C2v orientations were considered; for FrO2, the two lowest electronic states, 2A2 and 2B2, were considered in C2v symmetry. In addition, calculations were also performed on the x2 A2 ground states of RbO2 and CsO2 to derive ionization energies. Binding energies and heats of formation are also derived. The bonding in FrO2 is found to be less ionic than that of RbO2 and CsO2.
[Mh] Termos MeSH primário: Césio/química
Frâncio/química
Óxidos/química
Rubídio/química
[Mh] Termos MeSH secundário: Eletroquímica
Íons/química
Termodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Ions); 0 (Oxides); 15TEQ7D2QF (Francium); 1KSV9V4Y4I (Cesium); MLT4718TJW (Rubidium)
[Em] Mês de entrada:0706
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:060713
[St] Status:MEDLINE


  5 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15930310
[Au] Autor:Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
[Ad] Endereço:Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
[Ti] Título:Efforts to control the errant products of a targeted in vivo generator.
[So] Source:Cancer Res;65(11):4888-95, 2005 Jun 01.
[Is] ISSN:0008-5472
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Alpha-particle immunotherapy by targeted alpha-emitters or alpha-emitting isotope generators is a novel form of extraordinarily potent cancer therapy. A major impediment to the clinical use of targeted actinium-225 (225Ac) in vivo generators may be the radiotoxicity of the systemically released daughter radionuclides. The daughters, especially bismuth-213 (213Bi), tend to accumulate in the kidneys. We tested the efficacy of various pharmacologic agents and the effect of tumor burden in altering the pharmacokinetics of the 225Ac daughters to modify their renal uptake. Pharmacologic treatments in animals were started before i.v. administration of the HuM195-225Ac generator. 225Ac, francium-221 (221Fr), and 213Bi biodistributions were calculated in each animal at different time points after 225Ac generator injection. Oral metal chelation with 2,3-dimercapto-1-propanesulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant reduction (P < 0.0001) in the renal 213Bi uptake; however, DMPS was more effective than DMSA (P < 0.001). The results with DMPS were also confirmed in a monkey model. The renal 213Bi and 221Fr activities were significantly reduced by furosemide and chlorothiazide treatment (P < 0.0001). The effect on renal 213Bi activity was further enhanced by the combination of DMPS with either chlorothiazide or furosemide (P < 0.0001). Competitive antagonism by bismuth subnitrate moderately reduced the renal uptake of 213Bi. The presence of a higher target-tumor burden significantly prevented the renal 213Bi accumulation (P = 0.003), which was further reduced by DMPS treatment (P < 0.0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters.
[Mh] Termos MeSH primário: Actínio/administração & dosagem
Partículas alfa
Quelantes/farmacologia
Imunotoxinas/administração & dosagem
Rim/efeitos dos fármacos
Rim/efeitos da radiação
Radioimunoterapia/métodos
[Mh] Termos MeSH secundário: Actínio/sangue
Actínio/química
Actínio/farmacocinética
Animais
Anticorpos Monoclonais/administração & dosagem
Anticorpos Monoclonais/sangue
Anticorpos Monoclonais/química
Anticorpos Monoclonais/farmacocinética
Bismuto/química
Bismuto/farmacocinética
Feminino
Frâncio/química
Frâncio/farmacocinética
Imunotoxinas/sangue
Imunotoxinas/química
Imunotoxinas/farmacocinética
Rim/metabolismo
Linfoma/metabolismo
Linfoma/patologia
Linfoma/radioterapia
Macaca fascicularis
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Camundongos SCID
Succímero/farmacologia
Unitiol/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Chelating Agents); 0 (Immunotoxins); 15TEQ7D2QF (Francium); 4076-02-2 (Unithiol); DX1U2629QE (Succimer); NIK1K0956U (Actinium); U015TT5I8H (Bismuth)
[Em] Mês de entrada:0507
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050603
[St] Status:MEDLINE


  6 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11573800
[Au] Autor:Ma D; McDevitt MR; Finn RD; Scheinberg DA
[Ad] Endereço:Department of Pharmacology and Molecular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.
[Ti] Título:Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
[So] Source:Appl Radiat Isot;55(5):667-78, 2001 Nov.
[Is] ISSN:0969-8043
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bisumth-213, a short-lived alpha particle emitting radionuclide, is generated from the decay of 225Ac, which has a half-life of 10 days. The development of a clinical 225Ac/213Bi generator and the preparation of a 213Bi radiolabeled antibody for radioimmunotherapy of leukemia have been reported. The 225Ac decay scheme is complex; therefore a thorough understanding of the impact of both the parent 225Ac and its daughters on radiolabeling, purification, and quantification is necessary for optimal use of the generator system. This paper reports: (i) unique new methods to measure 221Fr, 213Bi, and 209Pb, the prominent daughters of 225Ac; and (ii) a quantitative evaluation of 225Ac/213Bi generator breakthrough and the radionuclidic purity of 213Bi labeled radiopharmaceutical dose formulations. A quantitative multi-dimensional proportional scanning method was employed to distinguish and measure specific daughter radionuclides. This method combines thin layer chromatography in two perpendicular directions with attenuated collimation as a function of time for data collection and analysis. Francium-221 and 213Bi eluted differentially from the generator, and 221Fr contributed minimally to unchelated 213Bi in the reaction and final products. Lead-209 was present in the reaction solution, but not strongly bound by the chelating moiety either (i) under the 213Bi labeling reaction conditions or (ii) following chelated 213Bi decay. As a consequence of incorporating several new procedures to the operation of the generator, 225Ac breakthrough in the final product was further reduced and represented a trivial contaminant in the final drug formulations.
[Mh] Termos MeSH primário: Actínio/isolamento & purificação
Bismuto/isolamento & purificação
Radioisótopos/isolamento & purificação
Compostos Radiofarmacêuticos/isolamento & purificação
[Mh] Termos MeSH secundário: Actínio/uso terapêutico
Frâncio/isolamento & purificação
Seres Humanos
Radioisótopos de Chumbo/isolamento & purificação
Leucemia/radioterapia
Radioquímica/métodos
Radioimunoterapia
Compostos Radiofarmacêuticos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Lead Radioisotopes); 0 (Radioisotopes); 0 (Radiopharmaceuticals); 15TEQ7D2QF (Francium); NIK1K0956U (Actinium); U015TT5I8H (Bismuth)
[Em] Mês de entrada:0112
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010928
[St] Status:MEDLINE


  7 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11539071
[Au] Autor:Khan F; Khandelwal GS; Wilson JW
[Ad] Endereço:Old Dominion University, Norfolk, Virginia 23508, USA.
[Ti] Título:Static multipole polarisabilities and second-order Stark shift in francium.
[So] Source:J Phys B At Mol Opt Phys;21:731-7, 1988.
[Is] ISSN:0953-4075
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The multipole polarisability of the ground state of francium is calculated by utilising both the variational technique of Davison and the quantum defect theory underlying the Bates-Damgaard method. This approach is also shown to yield reasonable results for other alkali atoms. Second-order Stark shift for the ground state of francium is presented as a function of field strength for possible future experimental comparison.
[Mh] Termos MeSH primário: Frâncio
Modelos Teóricos
[Mh] Termos MeSH secundário: Césio
Radiação Cósmica
Teoria Quântica
Rubídio
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
15TEQ7D2QF (Francium); 1KSV9V4Y4I (Cesium); MLT4718TJW (Rubidium)
[Em] Mês de entrada:9612
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:S
[Da] Data de entrada para processamento:880101
[St] Status:MEDLINE


  8 / 9 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:6395136
[Au] Autor:Yung CY
[Ti] Título:Neuropsychiatric manifestations of alkali metal deficiency and excess.
[So] Source:Pharmacol Biochem Behav;21 Suppl 1:71-5, 1984.
[Is] ISSN:0091-3057
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The alkali metals from the Group IA of the periodic table (lithium, sodium, potassium, rubidium, cesium and francium) are reviewed. The neuropsychiatric aspects of alkali metal deficiencies and excesses (intoxications) are described. Emphasis was placed on lithium due to its clinical uses. The signs and symptoms of these conditions are characterized by features of an organic brain syndrome with delirium and encephalopathy prevailing. There are no clinically distinctive features that could be reliably used for diagnoses. Sodium and potassium are two essential alkali metals in man. Lithium is used as therapeutic agent in bipolar affective disorders. Rubidium has been investigated for its antidepressant effect in a group of psychiatric disorders. Cesium is under laboratory investigation for its role in carcinogenesis and in depressive illness. Very little is known of francium due to its great instability for experimental study.
[Mh] Termos MeSH primário: Transtornos Mentais/induzido quimicamente
Metais Alcalinos/efeitos adversos
Doenças do Sistema Nervoso/induzido quimicamente
[Mh] Termos MeSH secundário: Césio/efeitos adversos
Césio/deficiência
Frâncio/efeitos adversos
Frâncio/deficiência
Seres Humanos
Deficiência de Potássio/psicologia
Rubídio/efeitos adversos
Rubídio/deficiência
Sódio/efeitos adversos
Sódio/deficiência
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Metals, Alkali); 15TEQ7D2QF (Francium); 1KSV9V4Y4I (Cesium); 9NEZ333N27 (Sodium); MLT4718TJW (Rubidium)
[Em] Mês de entrada:8502
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:840101
[St] Status:MEDLINE


  9 / 9 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:5709779
[Au] Autor:Carminati GM; D'Atri G
[Ti] Título:[The action of various substances on the function of the Starling rat heart-lung preparation].
[Ti] Título:L'azione di svariate sostanze sulla funzionalità del preparato cuore-polmoni sec. Starling nel ratto..
[So] Source:Arch Int Pharmacodyn Ther;176(1):134-48, 1968 Nov.
[Is] ISSN:0003-9780
[Cp] País de publicação:Belgium
[La] Idioma:ita
[Mh] Termos MeSH primário: Coração/efeitos dos fármacos
Pulmão/efeitos dos fármacos
[Mh] Termos MeSH secundário: Acetilcolina/farmacologia
Aminoácidos/farmacologia
Animais
Cálcio/farmacologia
Citratos/farmacologia
Epinefrina/farmacologia
Frâncio/farmacologia
Histamina/farmacologia
Magnésio/farmacologia
Métodos
Músculos/efeitos dos fármacos
Nucleosídeos/farmacologia
Nucleotídeos/farmacologia
Cloreto de Potássio/farmacologia
Piruvatos/farmacologia
Ratos
Serotonina/farmacologia
Cloreto de Sódio/farmacologia
Estrofantinas/farmacologia
Succinilcolina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acids); 0 (Citrates); 0 (Nucleosides); 0 (Nucleotides); 0 (Pyruvates); 0 (Strophanthins); 15TEQ7D2QF (Francium); 333DO1RDJY (Serotonin); 451W47IQ8X (Sodium Chloride); 660YQ98I10 (Potassium Chloride); 820484N8I3 (Histamine); I38ZP9992A (Magnesium); J2R869A8YF (Succinylcholine); N9YNS0M02X (Acetylcholine); SY7Q814VUP (Calcium); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:6904
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:681101
[St] Status:MEDLINE



página 1 de 1
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde